Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mesenchyme homeobox 1 (MEOX1) is a DNA-binding transcription factor that belongs to the homeobox family. It is essential for development, particularly for somite segmentation—the process that separates the vertebrae—and for proper skeletal patterning. MEOX1 regulates the expression of other genes by binding to their promoters, and is critical for vertebral and cranio-cervical joint formation. Pathogenic mutations in MEOX1 cause Klippel-Feil syndrome, a disorder characterized by congenital fusion of cervical vertebrae. In adult tissues, MEOX1 drives fibroblast activation and fibrotic remodeling in response to TGF-β signaling, making it an attractive therapeutic target in cardiac fibrosis. Additionally, MEOX1 has complex, context-dependent roles in cancer biology and immune cell regulation[1][3][4][6][7].
Not established for drugs; described as a potential druggable target in fibrotic disease, with experimental knockdown or inhibition impacting fibroblast activation and fibrosis[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mesenchyme homeobox 1 (MEOX1).